Cargando…

SGLT2 Inhibitors: A New Dawn for Recurrent/Refractory Cirrhotic Ascites

Detalles Bibliográficos
Autores principales:	Gao, Yuan, Wei, Lai, Zhang, Dorothy Da, Chen, Yu, Hou, Bing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	XIA & HE Publishing Inc. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666362/ https://www.ncbi.nlm.nih.gov/pubmed/34966642 http://dx.doi.org/10.14218/JCTH.2021.00418

Ejemplares similares

Weaning from concentrated ascites reinfusion therapy for refractory ascites by SGLT2 inhibitor
por: Miyamoto, Yasunori, et al.
Publicado: (2021)

Comment on ‘Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites’
por: Ahmed, Furqan
Publicado: (2017)

Consensus care recommendations for alfapump(®) in cirrhotic patients with refractory or recurrent ascites
por: Aagaard, Niels Kristian, et al.
Publicado: (2022)

Systemic hemodynamic and renal effects of midodrine and octreotide in cirrhotic patients with ascites
por: Kalambokis, Georgios N., et al.
Publicado: (2011)

Management of refractory cirrhotic ascites: challenges and solutions
por: Fukui, Hiroshi, et al.
Publicado: (2018)

Ascites reinfusion dialysis of refractory ascites as a bridge to kidney and liver transplantation in a patient on hemodialysis
por: Chang, Kyung Yoon, et al.
Publicado: (2017)

The Effects of SGLT2 Inhibitors on Liver Cirrhosis Patients with Refractory Ascites: A Literature Review
por: Miyamoto, Yasunori, et al.
Publicado: (2023)

Undergraduate research in India hoping for a new dawn
por: Chatterjee, Krishnarpan, et al.
Publicado: (2016)

The Palliative Management of Refractory Cirrhotic Ascites Using the PleurX(©) Catheter
por: Reinglas, Jason, et al.
Publicado: (2016)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Splanchnic and Systemic Hemodynamics in Cirrhotic Patients With Refractory Ascites. Effect of Peritoneovenous Shunting
por: Vons, Corinne, et al.
Publicado: (1991)

Surgical Treatment of Cirrhotic Ascites
Publicado: (1927)

Ayurvedic management of cirrhotic ascites
por: Aswathy, G., et al.
Publicado: (2016)

Ascitic Fluid Analysis in the Differential Diagnosis of Ascites: Focus on Cirrhotic Ascites
por: Huang, Lin-Lin, et al.
Publicado: (2014)

Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study
por: Lv, Xin-Yue, et al.
Publicado: (2020)

Dawn of Choosing Wisely Japan Student Committee
por: Soshi, Mano, et al.
Publicado: (2017)

Use of SGLT‐2 inhibitor in COVID‐19: A cautionary tale
por: Yousaf, Zohaib, et al.
Publicado: (2021)

A Metabolomic Analysis of Cirrhotic Ascites
por: Beyoğlu, Diren, et al.
Publicado: (2022)

Urea Transporter Inhibitor 25a Reduces Ascites in Cirrhotic Rats
por: Ying, Yi, et al.
Publicado: (2023)

Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites
por: Arase, Yoshitaka, et al.
Publicado: (2018)

First experience of a fully decentralized clinical trial: The dawn of a new era in oncology
por: Taniguchi, Hiroya, et al.
Publicado: (2023)

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
por: Yau, Kevin, et al.
Publicado: (2022)

Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?
por: Bernardi, Marco, et al.
Publicado: (2023)

Ascites-tap Simulator for Abdominal Examination and Removal of Ascites Fluid
por: Pakzad, Bahram, et al.
Publicado: (2019)

Nationwide Estimation of Eligibility for Endovascular Thrombectomy Based on the DAWN Trial
por: Lee, Keon-Joo, et al.
Publicado: (2018)

The dawn of directed acyclic graphs in primary care research and education
por: Iwata, Hiroyoshi, et al.
Publicado: (2023)

The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients
por: Soni, Shubham, et al.
Publicado: (2020)

High mortality of pneumonia in cirrhotic patients with ascites
por: Hung, Tsung-Hsing, et al.
Publicado: (2013)

Current approaches to the management of patients with cirrhotic ascites
por: Garbuzenko, Dmitry Victorovich, et al.
Publicado: (2019)

Rituximab pharmacokinetics in ascites and serum in the treatment of follicular lymphoma with massive ascites
por: Hiroshima, Yuki, et al.
Publicado: (2012)

An early decision of transjugular intrahepatic portosystemic shunt may be considered for non-malignant and non-cirrhotic portal vein thrombosis with ascites: a concise review of the theoretical possibility and practical difficulty
por: Qi, Xingshun, et al.
Publicado: (2016)

Recurrent abdominal pain and bloody ascites
por: Sung, Chih-Chien, et al.
Publicado: (2011)

The clinical advantage of fixed 8-mm diameter VCX stents over underdilated VTS stents is not established in refractory ascites
por: Mansour, Sohaïb, et al.
Publicado: (2021)

Fournier's Gangrene and Sodium-glucose Co-transporter 2(SGLT2) Inhibitors: Our Experience
por: Dass, Ashwitha S., et al.
Publicado: (2019)

Meta‐analysis of the effects of four factors on the efficacy of SGLT2 inhibitors in patients with HFrEF
por: Qiu, Mei, et al.
Publicado: (2021)

Letter Regarding “Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations”
por: Rico-Fontalvo, Jorge, et al.
Publicado: (2022)

Reply to: “The clinical advantage of fixed 8-mm diameter VCX stents over underdilated VTS stents is not established in refractory ascites”
por: Praktiknjo, Michael, et al.
Publicado: (2021)

JAK inhibitor, a new player for treatment-refractory microscopic colitis
por: Druez, Anne, et al.
Publicado: (2023)

Antimicrobial resistance of Pseudomonas aeruginosa in a Romanian hospital at the dawn of multidrug resistance
por: Gavriliu, Liana-Catalina, et al.
Publicado: (2016)

Euglycaemic ketoacidosis after abdominal surgery: Implications of SGLT2 inhibitors for anaesthesiologists – A case study
por: Kartha, Anandajith P., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mp5nc52bastrv38eb208td3fuo